BOSTON, MA, Day Zero Diagnostics, an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, announced the completion of a $21M venture equity financing.

The round was led by Sands Capital, with significant participation from new investors, including BD (Becton, Dickinson and Company), Panacea Venture and Hongkou Capital, alongside existing investors including Triventures and Golden Seeds. To date, Day Zero Diagnostics has raised over $33M in venture capital financing and over $10M in non-dilutive funding.